At Nvelop, we are working to address the complex challenge of effectively delivering genetic medicines to target cells within the body (in vivo) in order to help treat patients with previously undruggable diseases. Our team is advancing two next-generation delivery platforms, started in the labs of our scientific co-founders Dr. David Liu of the Broad Institute of MIT and Harvard, and Dr. Keith Joung formerly of Mass General Hospital. We will use these platforms to build a pipeline of therapeutics internally and to enable strategic partners. We are building a culture and organization to support this important mission, bringing together individuals that thrive in a supportive environment where diverse perspectives and a passion for discovery drive cutting-edge science and breakthrough medicines.
Read something that resonates? Reach out to careers@NvelopTx.com.
Company Details
- Employees
- 10
- Founded
- -
- Address
- 100 Technology Square, Cambridge,massachusetts 02139,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.nveloptx.com/
- Keywords
- Stem Cells.
- HQ
- Cambridge, Massachusetts
Nvelop Therapeutics Questions
Nvelop Therapeutics's website is https://www.nveloptx.com/
Nvelop Therapeutics's LinkedIn profile is https://www.linkedin.com/company/nveloptx
Nvelop Therapeutics has
10 employees.
View email and phone details for 10
employees at Nvelop Therapeutics.
Nvelop Therapeutics's industry is
Biotechnology Research
Nvelop Therapeutics's top competitors are
Myrobalan Therapeutics,
Delphia Therapeutics,
Fable Therapeutics,
Quiver Bioscience,
Nuvalent, Inc.,
Seaport Therapeutics,
Rapport Therapeutics,
Tessera Therapeutics,
Arena Bioworks,
Kalvista Pharmaceuticals, Inc..
Nvelop Therapeutics's categories are Biotechnology Research
Nvelop Therapeutics's founding year is 2022
